AMS •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 11:09
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeAMS
Market Capitalization1,638.2 mln
Float44.54 mln
Earnings Date05/06/2026
EPS
4.85
Solid
P / E
5.01
Undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
0.57
Highly suspicious
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
Business Description
Galapagos NV is a Belgian biotechnology company founded in 1999 that researches and develops new treatments for cancer and immune system diseases, with operations spanning the United States and Europe. Its most advanced drug candidates target conditions such as dermatomyositis, lupus, certain blood cancers, and multiple myeloma, with several currently being tested in clinical trials. The company works in partnership with Gilead Sciences and operates from its headquarters in Mechelen, Belgium.
